Michael Paidas, MD

Dr. Paidas’s notable contributions include: description of the regulatory factors of the Protein C system; clinical use of recombinant antithrombin in disease states; elucidation of the subsequent cardiovascular and non-cardiovascular health consequences of hypertensive disorders and preterm delivery in the largest population based studies published to date.

Dr. Paidas and collaborators have described the genomic and proteomic effects of Preimplantation Factor (PIF), a novel mammalian embryo derived factor which regulates maternal receptivity to pregnancy and possesses key immune modulatory properties. Subsequent animal studies using a synthetic analogue of native PIF have shown benefit in animal models related to a variety of immune diseases, including multiple sclerosis and graft versus host disease.

Dr. Paidas is the lead Principal Investigator of a multicenter preeclampsia treatment clinical trial, entitled Prospective Randomized Double-Blind, Placebo Controlled Evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia (PRESERVE-1).

Dr. Paidas has expertise in prenatal ultrasound, invasive fetal diagnostic and therapeutic procedures. His academic profile includes over 500 published manuscripts, abstracts, books, chapters, presentations or courses.

“Multigate Doppler with Global Acquisition and Signal Processing (G.A.S.P.) in the uteroplacental and fetal circulations.” This new non-invasive Doppler ultrasound technology is being applied to a variety of areas concerning women’s health, including early pregnancy assessment and gynecologic malignancy screening. This project is a collaboration between the Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, Department of Obstetrics and Gynecology; University of Milan, Bicocca, Milan, Italy; Department of Engineering, University of Florence, Florence, Italy; Esaote, Florence, Italy.

“Antithrombin levels preceding placenta mediated complications.” The objective of this study is to determine antithrombin and Preimplantation Factor levels in pregnancy complications, prior to the onset of clinical disease.

“Preimplantation factor (PIF): a biomarker for viable embryo selection after in vitro fertilization and for pregnancy outcome.” This proposal is a multicenter study which investigates the potential role of Preimplantation Factor as a diagnostic test in two settings; namely, to predict IVF success when measured in embryo culture media, and to predict viable pregnancy and a range of placenta mediated complications.

“Predicting Late and Early Perinatal Stroke in High Risk Pregnancies And High Risk Neonates.” The goal is to identify a very high risk population for perinatal stroke suitable for prevention or early treatment.

“Prospective Randomized Double-Blind, Placebo Controlled Evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Pre-term Pre-eclampsia (PRESERVE-1): RB AT PPE-01-13. Funding Agency: rEVO Biologics (formerly GTC Biotherapeutics). This is a multicenter, randomized, placebo controlled trial to determine whether maternal administration of recombinant antithrombin will prolong gestational age in the setting of preeclampsia at 24 to less than 28 wks.

“Neural Stem Cells and synthetic Preimplantation Factor (sPIF) to treat perinatal brain injury in the rodent. PreImplantation-Factor (PIF) +/- neural stem cells will be investigated as a therapeutic option to treat perinatal brain injury.